Page last updated: 2024-09-04

moxifloxacin and s 1743

moxifloxacin has been researched along with s 1743 in 12 studies

Compound Research Comparison

Studies (moxifloxacin)	Trials (moxifloxacin)	Recent Studies (post-2010) (moxifloxacin)	Studies (s 1743)	Trials (s 1743)	Recent Studies (post-2010) (s 1743)
3,157	552	1,690	1,228	569	704

Research

Studies (12)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	6 (50.00)	29.6817
2010's	6 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cammarota, G; Candelli, M; Cazzato, IA; Cremonini, F; Finizio, R; Gasbarrini, A; Gasbarrini, G; Nista, EC; Ojetti, V; Pignataro, G; Santoro, M; Zocco, MA	1
Cheon, JH; Jung, HC; Kim, JM; Kim, JS; Kim, N; Lee, DH; Song, IS	1
Jung, HC; Kang, JM; Kim, JS; Kim, N; Kim, YR; Lee, DH; Park, YS; Song, IS	1
Bästlein, E; Haferland, C; Jebens, C; Kirsch, C; Knoth, H; Kuhlisch, E; Lehn, N; Madisch, A; Miehlke, S; Morgner, A; Schneider-Brachert, W; Stolte, M; Zekorn, C	1
Cakal, B; Kiliç, ZM; Köksal, AS; Kuran, S; Nadir, I; Ozin, YO; Sahin, B	1
Hwang, TJ; Jung, HC; Kim, N; Lee, BH; Lee, DH; Nam, RH; Park, YS; Song, IS; Yoon, H	1
Amitrano, M; Grossi, L; Manzoli, L; Marzio, L; Sacco, F; Spezzaferro, M	1
Jung, HC; Kim, JY; Kim, N; Park, JH; Park, SY; Song, IS; Yoon, H	1
Berning, M; Jebens, C; Knoth, H; Krasz, S; Kuhlisch, E; Laass, MW; Lehn, N; Madisch, A; Miehlke, S; Morgner, A; Neumeyer, M; Schneider-Brachert, W; Stolte, M; Vieth, M; Zekorn, C	1
Jo, HJ; Kim, MS; Kim, N; Kim, SE; Lee, DH; Park, YS; Shin, CM	1
Almela, P; Angueira, T; Ariño, I; Barrio, J; Bermejo, F; Domínguez, JL; Domínguez-Muñoz, JE; Federico, A; Fernández, N; Fernandez-Bermejo, M; Ferrer-Barcelo, L; Gisbert, JP; Gomez, B; Gomez-Camarero, J; Gravina, AG; Lucendo, AJ; Marín, AC; Martin-Noguerol, E; Martorano, M; McNicholl, AG; Medina, E; Millastre, J; Miranda, A; Modolell, I; Molina-Infante, J; Ortuño, J; Perez-Aisa, Á; Perona, M; Rodríguez-Tellez, M; Romano, M	1
Choi, YJ; Kim, N; Kwon, YH; Lee, DH; Lee, JW; Lee, JY; Nam, RH; Suh, JH; Yoon, K	1

Trials

10 trial(s) available for moxifloxacin and s 1743

Article	Year
Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection. Alimentary pharmacology & therapeutics, 2005, May-15, Volume: 21, Issue:10 Topics: Adult; Amoxicillin; Aza Compounds; Drug Therapy, Combination; Dyspepsia; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Moxifloxacin; Patient Compliance; Prospective Studies; Quinolines; Tinidazole; Treatment Outcome	2005
Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection. Helicobacter, 2006, Volume: 11, Issue:1 Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Moxifloxacin; Organometallic Compounds; Patient Compliance; Quinolines; Tetracycline; Treatment Outcome	2006
Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy. Helicobacter, 2007, Volume: 12, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Moxifloxacin; Organometallic Compounds; Patient Compliance; Quinolines; Tetracycline	2007
One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter, 2008, Volume: 13, Issue:1 Topics: Adult; Aged; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Aza Compounds; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Mixed Function Oxygenases; Moxifloxacin; Polymorphism, Restriction Fragment Length; Prospective Studies; Quinolines; Rifabutin	2008
Moxifloxacine plus amoxicillin and ranitidine bismuth citrate or esomeprazole triple therapies for Helicobacter pylori infection. Digestive diseases and sciences, 2008, Volume: 53, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Aza Compounds; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Humans; Male; Middle Aged; Moxifloxacin; Pilot Projects; Prospective Studies; Quinolines; Ranitidine; Treatment Outcome; Young Adult	2008
Efficacy of four different moxifloxacin-based triple therapies for first-line H. pylori treatment. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2010, Volume: 42, Issue:2 Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aza Compounds; Breath Tests; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Moxifloxacin; Quinolines; Urea; Young Adult	2010
Effects of multistrain probiotic-containing yogurt on second-line triple therapy for Helicobacter pylori infection. Journal of gastroenterology and hepatology, 2011, Volume: 26, Issue:1 Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Bifidobacterium; Breath Tests; Chi-Square Distribution; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Lacticaseibacillus casei; Lactobacillus acidophilus; Male; Middle Aged; Moxifloxacin; Probiotics; Prospective Studies; Proton Pump Inhibitors; Quinolines; Republic of Korea; Streptococcus thermophilus; Time Factors; Treatment Outcome; Urease; Yogurt	2011
Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection. Helicobacter, 2011, Volume: 16, Issue:6 Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aza Compounds; Breath Tests; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Quinolines; Salvage Therapy; Time Factors; Treatment Outcome; Urea; White People	2011
Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy. BMC gastroenterology, 2013, Sep-19, Volume: 13 Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aza Compounds; Breath Tests; Disease-Free Survival; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Male; Metronidazole; Middle Aged; Moxifloxacin; Organometallic Compounds; Peptic Ulcer; Quinolines; Recurrence; Stomach Neoplasms; Tetracycline; Treatment Outcome	2013
Comparison of the efficacy of culture-based tailored therapy for Helicobacter pylori eradication with that of the traditional second-line rescue therapy in Korean patients: a prospective single tertiary center study. Scandinavian journal of gastroenterology, 2016, Volume: 51, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Organometallic Compounds; Prospective Studies; Proton Pump Inhibitors; Republic of Korea; Tertiary Care Centers; Tetracycline; Young Adult	2016

Other Studies

2 other study(ies) available for moxifloxacin and s 1743

Article	Year
Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate. Helicobacter, 2009, Volume: 14, Issue:5 Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Drug Resistance, Microbial; Drug Therapy, Combination; Esomeprazole; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Moxifloxacin; Prospective Studies; Quinolines; Treatment Outcome	2009
Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2015, Volume: 47, Issue:2 Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Cohort Studies; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Moxifloxacin; Prospective Studies; Proton Pump Inhibitors; Retreatment; Treatment Failure; Treatment Outcome; Urea	2015

Article

Year

Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate.

Helicobacter, 2009, Volume: 14, Issue:5

Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Drug Resistance, Microbial; Drug Therapy, Combination; Esomeprazole; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Moxifloxacin; Prospective Studies; Quinolines; Treatment Outcome

2009

Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2015, Volume: 47, Issue:2

Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Cohort Studies; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Moxifloxacin; Prospective Studies; Proton Pump Inhibitors; Retreatment; Treatment Failure; Treatment Outcome; Urea

2015